A randomised trial investigating the effect on biomedical (PSA) control and survival of different durations of adjuvant androgen deprivation in association with definite radiation treatment for localised carcinoma of the prostate (RADAR)
Six months of hormone treatment improves the results of radiotherapy for men with early prostate cancer. This trial will determine if adding another 12 months of hormone treatment after radiotherapy is even better. Bones are often affected by prostate cancer and can also be damaged by prolonged hormone treatment. Bisphosphonates are drugs that make bones stronger. This trial will also determine if treatment with a bisphosphonate can help prevent these bone problems.
Primary Sponsor
Final Accrual
1071
Closing Date of Accrual
2007
Trial Chairperson
Prof Jim Denham, Calvary Mater Newcastle, NSW
Trial Contact
Allison.Steigler@newcastle.edu.au
Clinical Trial Registration
Related Post
Trek4TROG team rise to Blue Mountains challenge
November 2024: Congratulations to the Trek4TROG team for successfully
Promising new results from RAIDER trial published
24 October 2024: Newly published findings from the TROG
